Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
  • Subscribe
Submit An Article

Latest Articles

  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler
    Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler
    • News

  • Crude falls below $90 US a barrel for the first time since Feb
    Crude falls below $90 US a barrel for the first time since Feb
    • Market Update

  • Buddy Technologies deemed worthless as receivers gut the company, acknowledge shortfall on secured debt
    Buddy Technologies deemed worthless as receivers gut the company, acknowledge shortfall on secured debt
    • News

  • Allegra’s 3D printed bone replacement proves safe for animals
    Allegra’s 3D printed bone replacement proves safe for animals
    • News

  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved
    Getting things from A to B isn’t as simple as it seems, until Yojee gets involved
    • News

  • Revasum makes leadership change amid cash flow struggles and semiconductor shipping delays
    Revasum makes leadership change amid cash flow struggles and semiconductor shipping delays
    • News

  • Markets remain bullish on earnings, but can the upward momentum last?
    Markets remain bullish on earnings, but can the upward momentum last?
    • Market Update

  • July 2022 Economic Wrap and the ASX Stocks that Moved
    July 2022 Economic Wrap and the ASX Stocks that Moved
    • Opinion

  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident
    NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident
    • News

  • Propel taps into booming pet funerals demand with crematorium acquisitions
    Propel taps into booming pet funerals demand with crematorium acquisitions
    • News

Race Oncology gains more patents for their cancer drug, Zantrene

  • In News
  • October 6, 2021
  • Samantha Freidin
Race Oncology gains more patents for their cancer drug, Zantrene

The field of cancer research is certainly buzzing with key research yielding new medications with the ultimate goal of improving patient outcomes. 

The mind numbingly broad list of diseases and disease subtypes that fall under the ‘cancer’ banner might make it seem like little to no progress is being made in conquering cancer. Look a little deeper and you’ll see the remarkable work of companies worldwide coming to fruition every day. 

Such is the case with Race Oncology (ASX: RAC) who have secured a fifth patent for their cancer drug, Zantrene in the United States. 

Designed as an inhibitor of the fat mass and obesity associated (FTO) protein, Zantrene is being explored for use in melanoma and kidney cancer as well as Acute Myeloid Leukaemia (AML), breast and ovarian cancers. Upregulation and overexpression of the FTO protein has been shown to act as a genetic driver of many cancers. 

Zantrene behaves like a chemotherapy drug but has reduced rates of cardiotoxicity (heart damage) to patients. 

Strengthening their IP position is key for the Company to ensure their market position. 

“This latest US patent provides Race with additional protection around the use, formulation and compositions of Zantrene (and related chemical structures) that improve the therapeutic benefit of Zantrene”, said Company CEO and Managing Director, Philip Lynch. 

En route to commercialisation, the Phase 2 /3 drug is now the subject of a robust set of patents as well as an FDA Orphan Drug designation and Rare Paediatric Disease designation. Race will be seeking FDA approval for Zantrene for a number of AML indications following promising Phase 2 trial results released last year. 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler - August 5, 2022
  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved - August 4, 2022
  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident - August 3, 2022
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler - August 5, 2022
  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved - August 4, 2022
  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident - August 3, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler - August 5, 2022
  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved - August 4, 2022
  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident - August 3, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

Copyright © 2020 The Sentiment. All rights reserved.